Gå til innhold

SSRI og kjønn. Hvilke SSRI aksepteres best?


Anbefalte innlegg

Et litt uvanlig fokus, men interessant og praktisk nyttig:

Abstract

Objective: The prevalence of depressive and anxiety disorders is higher in women than in men. In contrast, there is still no clear consensus on the existence of sex-related differences in the effectiveness of antidepressant treatments for these disorders. This real-world study used filled prescription sequences to compare antidepressant medications between women and men at a medication level according to their acceptability (ie, combination of efficacy and tolerability).

Methods: In a nationwide cohort from the French national health data system (Système National des Données de Santé [SNDS]), 1.2 million people were identified as new antidepressant users for any condition in 2011. The outcome was clinical acceptability as measured by the continuation/change ratio over the 6- month period following the introduction of the first-line treatment. Continuation was defined as at least 2 refills of the same treatment. Change was defined as at least one filled prescription of another antidepressant, an antipsychotic medication, or a mood stabilizer. Adjusted odds ratios (aORs) were computed through multivariable binary logistic regressions.

Results: Overall, after the first prescription of an antidepressant, the continuation/ change ratio was slightly higher for women than men (aOR [95% CI], 1.06 [1.05–1.08]), with escitalopram ranking first in both. Sex-by-medication interactions were significant for paroxetine (0.91 [0.88–0.95]) and fluoxetine (1.19 [1.12–1.26]) only. Specifically, fluoxetine was significantly more acceptable in female than in male participants (0.73 [0.70–0.75] vs 0.63 [0.60–0.67]), whereas paroxetine was more acceptable in male than in female participants (0.75 [0.72–0.78] vs 0.68 [0.66–0.70]).

Conclusion: These real-world data may help practitioners and policymakers prioritize choice of antidepressant medications in women and men.

J Clin Psychiatry 2024;85(4):23m15128

Author affiliations are listed at the end of this article.

Quick Links:

Fortsetter under...

Bli med i samtalen

Du kan publisere innhold nå og registrere deg senere. Hvis du har en konto, logg inn nå for å poste med kontoen din.

Gjest
Innholdet ditt inneholder uttrykk som vi ikke tillater. Vennligst endre innholdet ditt slik at det ikke lenger inneholder de markerte ordene nedenfor.
Skriv svar til emnet...

×   Du har limt inn tekst med formatering.   Lim inn uten formatering i stedet

  Du kan kun bruke opp til 75 smilefjes.

×   Lenken din har blitt bygget inn på siden automatisk.   Vis som en ordinær lenke i stedet

×   Tidligere tekst har blitt gjenopprettet.   Tøm tekstverktøy

×   Du kan ikke lime inn bilder direkte. Last opp eller legg inn bilder fra URL.

Laster...
×
×
  • Opprett ny...